Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Anyone wanna predict how many are dumping HGEN and buying CYDY?
It would be nice if the protocol is a phase 4 for CD12 with EUA approval.
"immediate EUA requests are pursued in multiple countries"
https://www.cytodyn.com/investors/news-events/press-releases/detail/513/cytodyn-files-new-protocol-with-u-s-fda-for-4-doses-of
FDA's in many countries will be working overtime this weekend.
On March 28 2021 CYDY is at $2.10, grip says it's going to $1, two days later it hits $2.99.
The wheels are spinning, flood gates are opening, Leronlimab is in the air
"Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn, commented, “We are very pleased to initiate sales of Vyrologix™ (leronlimab) in the Philippines as soon as we have CSP approved for patients."
https://www.cytodyn.com/investors/news-events/press-releases/detail/498/chiral-pharma-corp-to-assist-philippine-physicians-apply
"announced today the Republic of the Philippines, Department of Health, Food and Drug Administration (“Philippines FDA”) has approved the use of leronlimab to treat a COVID-19 patient under Compassionate Special Permit (“CSP”) pursuant to FDA Order No. 2016-005."
https://www.cytodyn.com/investors/news-events/press-releases/detail/510/the-philippines-fda-approves-the-use-of-leronlimab-to-treat
"CytoDyn will dedicate at least 200,000 vials (100,000 doses) of leronlimab from its inventory to Chiral Pharma Corp. for potential sales in the Philippines"
https://www.cytodyn.com/investors/news-events/press-releases/detail/498/chiral-pharma-corp-to-assist-philippine-physicians-apply
"The Company is shipping leronlimab to its partner, Chiral Pharma Corporation, its importer in the Philippines."
https://www.cytodyn.com/investors/news-events/press-releases/detail/510/the-philippines-fda-approves-the-use-of-leronlimab-to-treat
And locked and loaded with over a million vials of Leronlimab ready to sell it won't take long to get there. Unlike others that haven't even started manufacturing yet.
Eventually one way or another the U.S. will approve EUA for covid-19. The Philippines EUA approval will be any day now.
When the EUA approval for Leronlimab PR drops CYDY will gap up to $18.50
"Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn, commented, “We are very pleased to initiate sales of Vyrologix™ (leronlimab) in the Philippines as soon as we have CSP approved for patients."
https://www.cytodyn.com/investors/news-events/press-releases/detail/498/chiral-pharma-corp-to-assist-philippine-physicians-apply
"announced today the Republic of the Philippines, Department of Health, Food and Drug Administration (“Philippines FDA”) has approved the use of leronlimab to treat a COVID-19 patient under Compassionate Special Permit (“CSP”) pursuant to FDA Order No. 2016-005."
https://www.cytodyn.com/investors/news-events/press-releases/detail/510/the-philippines-fda-approves-the-use-of-leronlimab-to-treat
"CytoDyn will dedicate at least 200,000 vials (100,000 doses) of leronlimab from its inventory to Chiral Pharma Corp. for potential sales in the Philippines"
https://www.cytodyn.com/investors/news-events/press-releases/detail/498/chiral-pharma-corp-to-assist-philippine-physicians-apply
"The Company is shipping leronlimab to its partner, Chiral Pharma Corporation, its importer in the Philippines."
https://www.cytodyn.com/investors/news-events/press-releases/detail/510/the-philippines-fda-approves-the-use-of-leronlimab-to-treat
It's happening people, the wheels are turning, the flood gates are open
The Philippines have not only been looking at CD12 data, they have also been looking at eIND patients as well. When you add all that to the data released today approval is a lock. It looks like the 100,000 vials of Leronlimab could have been shipped there according to the PR.
https://finance.yahoo.com/news/chiral-pharma-corp-assist-philippine-210100495.html
The ultimate decider will be approval by a regulatory agency from a government. There are several different agencies looking and it will be approved by one soon. Then that opens the door for the rest to follow.
Now the race is on. Which country will approve Leronlimab first? My money is on the U.S. FDA.
Up 26%, see you're wrong, DEBUNKED AGAIN
That's the beautiful part, Philippines GOT Leronlimab. Now with this new data making approval a lock the 100,000 doses set aside for them will start over one hundred million in revenue for CytoDyn.
83% MORTALITY = 800% CYDY GAIN
Here's something NP implied in January...
Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn, commented, “We are very pleased to initiate sales of Vyrologix™ (leronlimab) in the Philippines as soon as we have CSP approved for patients. Under the CSP program,
Guess what....it's approved....let the party begin
$150,000,000 will be a nice start to CytoDyn's revenue could be as soon as this week
https://finance.yahoo.com/news/chiral-pharma-corp-assist-philippine-210100495.html
You don't get it. The flood gate is now opened. Chiral Pharma Corporation is getting EUA approval on CD12 and CD10 data not the one patient. The one patient is an indicator that the Philippines FDA likes what they see otherwise it would have been rejected.
There's a difference between rlftf and CYDY, first they have over 4 billion shares, that's enough to keep away many investors, rlftf has the one indication and covid could be a declining market, second CYDY just needs an open door once they have any approval the other indications will follow, CYDY value will snowball.
The FDA will approve EUA for Leronlimab to treat covid-19. The only question is will they be the first country to approve.
Panning out fine??!! It's failed twice already, changing the trial after the first failure is somewhat understandable but the second time is a hail mary.
So they are a heartless company? They have a supposed wonder drug and they stop giving it to patients because what? To save money? Most likely they applied and were denied. CytoDyn on the other hand not only was approved for OLE they went out of their way and got approval for additional eIND to help save people's lives.
Lenz stopped recruiting for their trial most likely they were denied OLE. Unlike Leronlimab, CD12 still recruiting and OLE still approved.
Harish Seethamraju, M.D., Medical Director for the Mount Sinai Lung Transplantation Program, commented, “The CD12 trial results are very promising and leronlimab may be the only safe medication to help critically ill patients.”
So you're saying it's a bad thing that Leronlimab cured Charlie Sheen from HIV?
So the argument from people that are terrified CytoDyn applied for EUA is that it's all a conspiracy and doctor's, scientist from across the United States are in on it.
Here's another crazy scientist/doctor in on the conspiracy
https://www.montefiore.org/body.cfm?id=1738&action=detail&ref=1746
So your argument is some crazy conspiracy? Everyone is in on it?, Charlie Sheen, Bruce Patterson, the FDA?
HGEN trial has failed twice and investors are dumping. Why would anyone be invested in a stock whose drug is against all odds even if it is good?
Why does Leronlimab being approved for EUA to treat covid-19 terrify people? It seems strange to say the least that CytoDyn applying for EUA would draw constant non-stop false accusations and outright lies. The only logical explanation are these same people know and believe that Leronlimab will be approved for EUA and they are desperately trying to talk CYDY share price lower so they can cover their short position.
CYDY will be back to $4 with longhaulers and protocol approved PR's. Both should be out this coming week. EUA sends this to double digits.
HGEN is tanking this close to TLD for a reason. The reason is the trial already failed twice. It will not meet it's endpoints, investors know this, they are selling.
Nuh-un